jpoly4

Hiring During COVID-19: Business as Usual in the New Normal

As the COVID-19 pandemic continues to usher in an unprecedented era for the global economy and businesses worldwide, Xtalks recently spoke to the CEOs of several companies in the pharmaceutical and biotechnology sectors to learn about how they are navigating the current situation with respect to hiring and recruitment.

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to AI and Longevity drug discovery, there are already several companies out there leveraging the power of machine learning, and we recently covered the $6 million funding injection received by Fountain Therapeutics for …

Fountain’s ‘hypothesis-free’ approach to Longevity AI Read More »

Fountain Therapeutics Closes $6 Million Series A-1 Financing

Closing brings total Series A financing sum to $11 million Funds to support expansion of team, technology platform and in vivo preclinical drug testing SAN FRANCISCO, May 19, 2020 (GLOBE NEWSWIRE) — Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the closing of a …

Fountain Therapeutics Closes $6 Million Series A-1 Financing Read More »

Scroll to Top